Loading
A phase 2 trial of Catumaxomab in Ovarian cancer, run by Neovii Biotech, completed.
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy is a phase 2 interventional study registered as NCT00377429 by Neovii Biotech, with 47 participants recorded, started 2006-09 and reaching its primary completion in 2008-02. Interventions recorded: catumaxomab. Conditions recorded: Ovarian Cancer.
Linked to the drug Catumaxomab because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
47 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2012-07-11), not from a publication
Sourcerange 21.3 to 141.0; Figures from the ClinicalTrials.gov results section (first posted 2012-07-11), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants Who Completed a 4-dose Series of Catumaxomab Infusions (Defined as 10-20-50-150 Micrograms) Within 21 Daysprimary | Catumaxomab | 47 | 29 participants | - | - | link |
| Median Time of Progression-free Survival in Weeks (Post-study for 24 Months) | Catumaxomab | 43 | 86.1 weeks | - | - | link |
Shares Neovii, Catumaxomab, Ovarian cancer and the tag pipeline.
Shares Catumaxomab, Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.